Published in Haemophilia on September 02, 2010
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01
Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 2.92
Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther (2015) 0.97
Prophylaxis for adults with haemophilia: one size does not fit all. Blood Transfus (2012) 0.91
Gene therapy in an era of emerging treatment options for hemophilia B. J Thromb Haemost (2015) 0.78
Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfus (2014) 0.77
Issues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics. J Blood Med (2015) 0.75
How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood (2016) 0.75
Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations? Thromb J (2016) 0.75
The History of Clotting Factor Concentrates Pharmacokinetics. J Clin Med (2017) 0.75
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (2010) 13.59
Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature (1994) 9.06
Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol (1991) 7.67
The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA (1995) 7.31
Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation (1997) 7.03
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet (1994) 5.58
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet (1994) 5.45
Oral contraceptives and the risk of myocardial infarction. N Engl J Med (2001) 5.18
Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med (1995) 5.16
Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med (1995) 5.12
Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet (1995) 5.10
The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology (1995) 5.08
Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet (1997) 5.04
Cardiovascular mortality in Dutch men during 1996 European football championship: longitudinal population study. BMJ (2001) 4.87
End of the line for "third-generation-pill" controversy? Lancet (1997) 4.63
The epidemiology of heart failure. Eur Heart J (1997) 4.31
The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ (2009) 4.18
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet (1992) 4.15
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood (1995) 4.12
Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med (1996) 4.11
Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost (2007) 4.09
Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet (1995) 4.01
Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke (2001) 3.99
Early outcome after off-pump versus on-pump coronary bypass surgery: results from a randomized study. Circulation (2001) 3.96
J-shaped relation between change in diastolic blood pressure and progression of aortic atherosclerosis. Lancet (1994) 3.95
Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology (1994) 3.75
Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation (1994) 3.65
External validation is necessary in prediction research: a clinical example. J Clin Epidemiol (2003) 3.49
Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost (2006) 3.49
Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ (1995) 3.42
Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol (1998) 3.37
Increased fetal loss in women with heritable thrombophilia. Lancet (1996) 3.34
The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. Ophthalmology (1994) 3.30
Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J (1999) 3.18
The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J (2001) 3.07
Is publication bias a medical problem? Lancet (1993) 3.04
Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. Circulation (2005) 2.99
Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia (1997) 2.82
Genetic association of apolipoprotein E with age-related macular degeneration. Am J Hum Genet (1998) 2.82
Age-related macular degeneration and smoking. The Rotterdam Study. Arch Ophthalmol (1996) 2.80
Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke (1997) 2.79
Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc (1999) 2.71
Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med (1995) 2.70
Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med (1993) 2.70
Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ (1994) 2.60
stevor and rif are Plasmodium falciparum multicopy gene families which potentially encode variant antigens. Mol Biochem Parasitol (1998) 2.58
Oral contraceptives and the risk of venous thrombosis. N Engl J Med (2001) 2.57
Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med (1999) 2.53
Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study. Stroke (2001) 2.49
A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab (1998) 2.45
Dietary antioxidants and cognitive function in a population-based sample of older persons. The Rotterdam Study. Am J Epidemiol (1996) 2.45
Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ (2001) 2.43
Primary open-angle glaucoma, intraocular pressure, and systemic blood pressure in the general elderly population. The Rotterdam Study. Ophthalmology (1995) 2.43
Does drug treatment improve survival? Reconciling the trials in mild-to-moderate hypertension. J Hypertens (1995) 2.40
High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 2.39
Antipsychotic medication and venous thrombosis. Br J Psychiatry (2001) 2.37
Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab (2000) 2.36
Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med (2001) 2.35
Activation of coagulation system during air travel: a crossover study. Lancet (2006) 2.32
Comparison between measures of atherosclerosis and risk of stroke: the Rotterdam Study. Stroke (2003) 2.31
Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology (1995) 2.30
Cigarette smoking and the risk of venous thromboembolism: the Tromsø Study. J Thromb Haemost (2012) 2.30
Limitations of sensitivity, specificity, likelihood ratio, and bayes' theorem in assessing diagnostic probabilities: a clinical example. Epidemiology (1997) 2.28
Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation (1998) 2.26
The dissociation of discriminative and conditioned reinforcing functions of stimuli with changes in deprivation. J Exp Anal Behav (1968) 2.24
Carotid intima-media thickness at different sites: relation to incident myocardial infarction; The Rotterdam Study. Eur Heart J (2002) 2.22
Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA (1999) 2.21
Incidence, risk, and case fatality of first ever stroke in the elderly population. The Rotterdam Study. J Neurol Neurosurg Psychiatry (2003) 2.18
Mortality due to pulmonary embolism, myocardial infarction, and stroke among incident dialysis patients. J Thromb Haemost (2012) 2.17
QTc dispersion predicts cardiac mortality in the elderly: the Rotterdam Study. Circulation (1998) 2.15
Cognitive correlates of ventricular enlargement and cerebral white matter lesions on magnetic resonance imaging. The Rotterdam Study. Stroke (1994) 2.14
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost (2005) 2.13
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation (2004) 2.12
Postprandial triglyceride response in young adult men and familial risk for coronary atherosclerosis. Ann Intern Med (1994) 2.11
Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ (1996) 2.11
Preoperative prediction of severe postoperative pain. Pain (2003) 2.11
Increase in hospital admission rates for heart failure in The Netherlands, 1980-1993. Heart (1996) 2.10
Low testosterone concentrations and the symptoms of testosterone deficiency according to the Androgen Deficiency in Ageing Males (ADAM) and Ageing Males' Symptoms rating scale (AMS) questionnaires. Clin Endocrinol (Oxf) (2011) 2.09
Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. The Rotterdam Study. Eur Heart J (1999) 2.09
Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study) Blood (1995) 2.09
Associations of radiological osteoarthritis of the hip and knee with locomotor disability in the Rotterdam Study. Ann Rheum Dis (1998) 2.08
Current perspective of venous thrombosis in the upper extremity. J Thromb Haemost (2008) 2.06
Use of preventive measures for air travel-related venous thrombosis in professionals who attend medical conferences. J Thromb Haemost (2006) 2.06
Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med (1998) 2.05
Distribution of central corneal thickness and its association with intraocular pressure: The Rotterdam Study. Am J Ophthalmol (1997) 2.04
[Nutrition and health--hypertension]. Ned Tijdschr Geneeskd (2003) 2.04
[Short preoperative health assessment proposed by the Health Council not useful in clinical practice]. Ned Tijdschr Geneeskd (2001) 2.04
Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost (1999) 2.04
The family history and inherited thrombophilia. Br J Haematol (1994) 2.03
Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study. Am J Epidemiol (1995) 2.02
Updating methods improved the performance of a clinical prediction model in new patients. J Clin Epidemiol (2007) 2.01
Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost (2006) 2.01
Seasonal variation of venous thrombosis: a consecutive case series within studies from Leiden, Milan and Tromsø. J Thromb Haemost (2012) 2.01
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet (1995) 2.00